SEC31A: A Web1-like Protein as a Drug Target or Biomarker (G22872)

Target Name: SEC31A

NCBI ID: G22872

SEC31A

SEC31A: A Web1-like Protein as a Drug Target or Biomarker

SEC31A is a protein that belongs to the Sec31 family, which is a well-known protein that is involved in various cellular processes, including cell signaling, DNA replication, and protein-protein interactions. The Sec31 family has been identified as a potential drug target or biomarker due to its unique structure and its involvement in various cellular processes. In this article, we will discuss SEC31A as a drug target or biomarker in more detail.

Structure and Function

SEC31A is a 31-kDa protein that consists of 31 amino acid residues. It has a unique structure that is similar to that of the Sec31 protein, which is a key protein involved in the central dogma of molecular biology, which states that protein structure determines function. SEC31A has a similar X-ray structure to Sec31, with a conserved catalytic core and a N-terminal region that is involved in protein-protein interactions.

SEC31A is involved in various cellular processes, including DNA replication, gene expression, and protein-protein interactions. One of the unique features of SEC31A is its ability to interact with other proteins, including the transcription factor, p53. This interaction between SEC31A and p53 suggests that it may be involved in the regulation of gene expression. Additionally, SEC31A has been shown to interact with the protein, Top20, which is involved in the regulation of DNA replication. This interaction between SEC31A and Top20 suggests that it may be involved in the regulation of DNA replication.

Drug Target Potential

SEC31A's unique structure and its involvement in various cellular processes make it an attractive drug target. The Sec31 family has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and protein-protein interactions. As a result, SEC31A may be a potential drug target for various diseases.

One of the potential benefits of targeting SEC31A is its potential to treat cancer.SEC31A has been shown to play a role in the regulation of cell proliferation, which is a key factor in the development and progression of cancer. Additionally, SEC31A has been shown to interact with the transcription factor, p53, which is a key regulator of cancer growth. Therefore, targeting SEC31A with drugs that inhibit its function may be an effective way to treat cancer.

Another potential benefit of targeting SEC31A is its potential to treat neurodegenerative diseases.SEC31A has been shown to play a role in the regulation of protein-protein interactions and has been implicated in the development and progression of neurodegenerative diseases. Therefore, targeting SEC31A with drugs that modulate its function may be an effective way to treat neurodegenerative diseases.

Biomarker Potential

SEC31A may also be a useful biomarker for certain diseases. Its unique structure and its involvement in various cellular processes make it an attractive candidate for use as a biomarker. For example, SEC31A may be used as a biomarker for cancer, as its expression is often elevated in cancer cells. Additionally, SEC31A may be used as a biomarker for neurodegenerative diseases, as its expression is often decreased in neurodegenerative disease cells.

Conclusion

In conclusion, SEC31A is a protein that is involved in various cellular processes and has been identified as a potential drug target or biomarker. Its unique structure and its involvement in various cellular processes make it an attractive candidate for both drug targeting

Protein Name: SEC31 Homolog A, COPII Coat Complex Component

Functions: Component of the coat protein complex II (COPII) which promotes the formation of transport vesicles from the endoplasmic reticulum (ER) (PubMed:10788476). The coat has two main functions, the physical deformation of the endoplasmic reticulum membrane into vesicles and the selection of cargo molecules (By similarity)

The "SEC31A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEC31A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets